GLP-1 Drugs Linked to Reduced Psychiatric Hospitalizations in Schizophrenia Patients with Diabetes

A new study in The Lancet Psychiatry suggests that GLP-1 receptor agonists, commonly used for diabetes and weight management, may offer mental health benefits. Analyzing U.S. health records of over 70,000 adults, researchers found that patients with both schizophrenia and Type 2 diabetes taking GLP-1 drugs were 24% less likely to require psychiatric hospitalization or emergency department visits. This association was primarily observed with semaglutide, liraglutide, and tirzepatide.